A Novel Multi-Epitope Vaccine Design Targeting E۱/E۲ Envelope Glycoprotein of Chikungunya Virus: An Immunoinformatics Approach

سال انتشار: 1403
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 63

فایل این مقاله در 16 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_JMCH-7-2_006

تاریخ نمایه سازی: 15 آذر 1402

چکیده مقاله:

The Chikungunya virus (CHIKV), a zoonotic virus transmitted through mosquito bites, can cause dengue-like fever in humans. Despite the lack of specific clinical treatments and vaccines, there has been limited attention given to CHIKV in recent decades. This study utilized an immunoinformatics approach to design a potential multi-epitope vaccine for CHIKV. The CHIKV multi-epitope vaccine (CHIKV-MEV) was created by combining predicted linear B-cell lymphocyte (LBL), cytotoxic T-lymphocyte (CTL), and helper T-lymphocyte (HTL) epitopes targeting the viral envelope glycoprotein E۱/E۲ of CHIKV. The selection of each epitope was based on parameters such as antigenicity, immunogenicity, toxicity, and allergenicity. These selected epitopes were incorporated to generate refined and validated ۳D models of CHIKV-MEV. Molecular docking simulations were performed to assess the interaction between the generated ۳D model of CHIKV-MEV and TLR-۱/۲. Immune response simulations and population coverage analysis were conducted to evaluate the potential effectiveness of the vaccine. The proposed CHIKV-MEV consists of ۴۳۹ amino acids, encompassing ۱۸ epitopes, and exhibits predicted properties of being antigenic, immunogenic, non-allergenic, and non-toxic. The binding energy of -۱۰۷۹.۰ kcal/mol indicated that CHIKV-MEV can interact with TLR-۱/۲, leading to immune responses. Immune response simulations of CHIKV-MEV demonstrated an increase in immunoglobulin levels, as well as population of LBL, CTL, and HTL, and cytokine levels associated with the defence against viral infections. Furthermore, based on compatibility with human leukocyte antigen (HLA), CHIKV-MEV potentially covers ۹۶.۲۵% of the global population. This research contributes to the development of a globally applicable multi-epitope peptide-based vaccine against CHIKV, supported by comprehensive in vitro and in vivo studies.

نویسندگان

M. Nizam Zulfi Zakaria

Department of Biology, Faculty of Mathematics and Life Sciences, Universitas Brawijaya, Malang, Indonesia

Ahmad Fariduddin Aththar

Department of Biology, Faculty of Mathematics and Life Sciences, Universitas Brawijaya, Malang, Indonesia

Michelle Fai

Department of Biology, Faculty of Mathematics and Life Sciences, Universitas Brawijaya, Malang, Indonesia

Syeftyan Muhammad Ali Hamami

Department of Biology, Faculty of Mathematics and Life Sciences, Universitas Brawijaya, Malang, Indonesia

Viol Dhea Kharisma

Generasi Biologi Indonesia Foundation, Gresik, Indonesia

Ahmad Affan Ali Murtadlo

Generasi Biologi Indonesia Foundation, Gresik, Indonesia

Arif Nur Muhammad Ansori

Generasi Biologi Indonesia Foundation, Gresik, Indonesia

Teguh Hari Sucipto

Dengue Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia

Rahadian Zainul

Department of Chemistry, Faculty of Mathematics and Life Sciences, Universitas Negeri Padang, Padang, Indonesia

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • . Voss J.E., Vaney M.C., Duquerroy S., Girard-Blanc C., Crublet ...
  • . Pua G.A., Fatimawali F., Antasionasi I., Review of Chikungunya ...
  • نمایش کامل مراجع